The popularity website of Sildenafil initially drove a boom for pharma, but recent changes present a complicated outlook for investors. Off-patent versions are eating into revenue, and persistent litigation add further complexity to the equation. While some companies could still gain from complementary products, the overall trajectory suggests a me